prikaz prve stranice dokumenta Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
  Download
PDF 148.43 KB
Scientific paper - Original scientific paper
Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
Dermatology Reports, 11 (2019), 1; 7965. https://doi.org/10.4081/dr.2019.7965
Dehpouri, Tannaz; Rahmatpour Rokni, Ghasem; Ahangar Narenjbon, Nematollah; Goldust, Mohamad; Yamauchi, Paul S.; Wollina, Uwe; Lotti, Torello; Kircik, Leon; Di Lernia, Vito Giuseppe; Sonthalia, Sidharth; Vojvodic, Aleksandra; Szepietowski, Jacek; Bahadoran, Philippe; Errichetti, Enzo; Cantisani, Carmen; Atzori, Laura; Rezaee, Elham; Kutlubay, Zekayi; Engin, Burhan; Nisticò, Steven; Damiani, Giovanni; Conic, Rosalynn R.Z.; Goren, Andy; Čabrijan, Leo; Tchernev, Georgi More authors...

Cite this document

Dehpouri, T., Rahmatpour Rokni, G., Ahangar Narenjbon, N., Goldust, M., Yamauchi, P. S., Wollina, U. ... Tchernev, G. (2019). Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports, 11. (1). doi: 10.4081/dr.2019.7965

Dehpouri, Tannaz, et al. "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study." Dermatology Reports, vol. 11, no. 1, 2019. https://doi.org/10.4081/dr.2019.7965

Dehpouri, Tannaz, Ghasem Rahmatpour Rokni, Nematollah Ahangar Narenjbon, Mohamad Goldust, Paul S. Yamauchi, Uwe Wollina, Torello Lotti, et al. "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study." Dermatology Reports 11, no. 1 (2019). https://doi.org/10.4081/dr.2019.7965

Dehpouri, T., et al. (2019) 'Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study', Dermatology Reports, 11(1). doi: 10.4081/dr.2019.7965

Dehpouri T, Rahmatpour Rokni G, Ahangar Narenjbon N, Goldust M, Yamauchi PS, Wollina U, and sur.. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatology Reports [Internet]. 2019 May 09 [cited 2024 December 26];11(1). doi: 10.4081/dr.2019.7965

T. Dehpouri, et al., "Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study", Dermatology Reports, vol. 11, no. 1, May 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:654504. [Accessed: 26 December 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study
AuthorTannaz Dehpouri
AuthorGhasem Rahmatpour Rokni
AuthorNematollah Ahangar Narenjbon
AuthorMohamad Goldust
AuthorPaul S. Yamauchi
AuthorUwe Wollina
AuthorTorello Lotti
AuthorLeon Kircik
AuthorVito Giuseppe Di Lernia
AuthorSidharth Sonthalia
AuthorAleksandra Vojvodic
AuthorJacek Szepietowski
AuthorPhilippe Bahadoran
AuthorEnzo Errichetti
AuthorCarmen Cantisani
AuthorLaura Atzori
AuthorElham Rezaee
AuthorZekayi Kutlubay
AuthorBurhan Engin
AuthorSteven Nisticò
AuthorGiovanni Damiani
AuthorRosalynn R.Z. Conic
AuthorAndy Goren
AuthorLeo Čabrijan
AuthorGeorgi Tchernev
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Dermatovenerology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Dermatovenerology
Abstract (english)
Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDermatology Reports
Numberingvol. 11, no. 1, 7965
p-ISSN2036-7392
e-ISSN2036-7406
DOIhttps://doi.org/10.4081/dr.2019.7965
URN:NBNurn:nbn:hr:184:654504
Publication2019-05-09
Document URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6547029/pdf/dr-11-1-7965.pdf
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2022-02-21 08:47:30